The role of molecular probes and other markers in the diagnosis and characterization of malignancy
Prostate cancer: epidemiology, histology, diagnosis and staging
Prostate cancer therapy
Systemic and mucocutaneous reactions to chemotherapy
Written by highly eminent authors, Prostate Cancer - a handbook in the Dana-Farber Cancer Institute series - is produced in full color and is richly illustrated throughout, providing a review of each cancer including its incidence, epidemiology, etiology and histopathology, together with the clinical features. Diagnostic studies and current clinical and pathological staging are also given. Detailed tables are provided with histopathological classification, diagnostic studies and, when important, prognostic factors. Current therapies are also discussed in detail, together with useful algorithms to aid treatment decisions. Practical issues relating to management are also given such as dealing with systemic and mucocutaneous reactions to chemotherapy, including alopecia, fatigue and extravasation.
- Comprehensive coverage - from risk and prevention, and screening and diagnosis, through to treatment options (chemotherapy, radiation therapy, biological response modifiers)
- Attractively designed aids with instant access to the information
- Contains useful algorithms to aid management decisions
- Discusses practical management of problems in cancer therapy including fever, vomiting, alopecia, fatigue, pain and cachexia
- Provides practical advice regarding drug administration
- Linked to the hugely successful Dana-Farber Atlas of Diagnostic Oncology
- No. of pages:
- © Mosby Ltd. 2007
- 22nd June 2007
- Mosby Ltd.
- Paperback ISBN:
Arthur T. Skarin, MD, FACP, FCCP, earned his MD from the State University of New York at Buffalo in 1961, and received postgraduate training in internal medicine at the Millard Fillmore Teaching Hospital in Buffalo. After a fellowship in hematology and oncology at Boston City Hospital, he joined Brigham and Women’s Hospital and Dana-Farber Cancer Institute (DFCI) in 1970. He served as Clinical Director of the DFCI Hematology Laboratory as well as Chairman of the Laboratory Committee from 1970 to 1998. He established the multimodality thoracic oncology clinic in 1975 and has served as Medical Director since then. During that time he also was chair of the human protection committee (IRB) for 12 years and became Associate Professor of Medicine at Harvard Medical School. He has been the Principal Investigator (PI) as well as site PI on numerous clinical research Phase I, II and III trials, both at DFCI Partners Cancer Care and the Cancer and Leukemia Group B (CALGB). He was appointed a Research Subject Advocate (RSA) in 2002 for NIH funded studies at the Brigham and Women’s Hospital General Clinical Research Center (GCRC) and DFCI. Dr. Skarin is a board member of the American Journal of Oncology Review, the Journal of Cinical Oncology, Hospital Physician and also president of the Massachusetts Society of Clinical Oncologists. He has published 150 original articles, 97 abstracts, 67 chapters in books and 4 books.
Associate Professor of Medicine, Harvard Medical School, Boston, MA, USA; Senior Attending Physician, Dana-Farber Cancer Institute, Boston, MA, USA
Clinical Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA
Consultant Medical Oncologist, Christie Hospital NHS Trust, Manchester, UK